Mantle Cell Lymphoma

Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.

Avyakta Kallam, MBBS, gave a look as to why she decided to compile a comprehensive review in mantle cell lymphoma.

Avyakta Kallam, MBBS and Julie Vose MD, MBA, review available treatment options for patients with mantle cell lymphoma.

Findings from a real-world study suggest the importance of novel agents for improving efficacy outcomes and tolerability in elderly patients with mantle cell lymphoma.

Levels of soluble CD163 appear to be higher in those with p53 abnormalities, elevated lactate dehydrogenase, and low hemoglobin in a study cohort of patients with mantle cell lymphoma.

Umbralisib in combination with ublituximab and venetoclax appears tolerable and yields responses in a small cohort of patients with mantle cell lymphoma.

Patients with mantle cell lymphoma who undergo a shorter diagnosis to treatment interval also have worse clinical and disease characteristics on average than those with a longer interval.

Treatment with liso-cel produces low rates of severe cytokine release syndrome in relapsed/refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.

The non-covalent BTK inhibitor shows an encouraging duration of response in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma, according to data.

Overall survival rates at 12 and 36 months appear to favor the addition of acalabrutinib to bendamustine and rituximab in the treatment of those with mantle cell lymphoma in a phase 1b trial.

Rituximab plus bendamustine and cytarabine continues to show clinical efficacy and favorable outcomes in a population of elderly patients with mantle cell lymphoma.

Liso-cel produces no new safety signals in relapsed or refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.

Primary outcome data from phase 3 confirmatory studies evaluating ibrutinib in mantle cell lymphoma and marginal zone lymphoma are insufficient to support conversion to full FDA approval in these indications.

Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.

Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China.

Investigators indicate that although avoiding efficient mantle cell lymphoma treatment due to late effects may seem okay, most long-term health care needs are disease related in patients up to 70 years.

Findings from a multicenter analysis indicate that tumor lysis syndrome is a notable risk in patients with mantle cell lymphoma receiving treatment with venetoclax.

Prior exposure to recent bendamustine and having tumor-intrinsic features were associated with inferior efficacy outcomes following treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma.

Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.

LP-284, which now has orphan drug designation from the FDA for mantle cell lymphoma, yielded positive preclinical data at the 2022 American Society of Hematology Annual Meeting and Exposition.

In a population of patients with patients with mantle cell lymphoma and follicular lymphoma, zandelisib plus zanubrutinib did not increase the rate or severity of class-related adverse effects.

Lenalidomide plus rituximab consolidation therapy prior to bendamustine/rituximab induction did not significantly improve progression-free survival in patients with mantle cell lymphoma in the phase 2 NCTN E1411 trial.

Treatment with the BTK inhibitor ibrutinib plus the CAR-T cell therapy tisagenlecleucel produced a high rate of durable responses in patients with relapsed/refractory mantle cell lymphoma after they stopped treatment at 6 months, according to early data from the TARMAC trial.

Acalabrutinib produced promising response rates in combination with lenalidomide and rituximab in previously untreated patients with mantle cell lymphoma.

Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.

Ziolvertamab and Ibrutinib combination therapy demonstrated an overall response rate of 89.3% and 91.2% in patients with mantle cell lymphoma and chronic lymphocytic leukemia, respectively.

The use of a fixed-duration regimen of glofitamab several days after pretreatment with obinutuzumab was associated with high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Real-world data show effective outcomes following ibrutinib and rituximab treatment in patients with relapsed/refractory mantle cell lymphoma with bone marrow involvement.

Andre H. Goy, MD, discussed the most pressing unresolved questions in the current treatment of MCL in an interview with the journal ONCOLOGY.